Qiming Bio

Venus Medtech is a leading Chinese medical device company specializing in the development and commercialization of transcatheter heart valve therapies. The company is best known for its VenusA-Valve, which was the first transcatheter aortic valve implantation (TAVI) device approved by the National Medical Products Administration (NMPA) in China. Beyond aortic therapies, Venus Medtech is expanding its portfolio to include transcatheter pulmonary, mitral, and tricuspid valve replacement and repair systems. The company also develops renal denervation (RDN) systems for the treatment of hypertension and other structural heart disease solutions. Venus Medtech aims to provide comprehensive, minimally invasive solutions for patients with structural heart diseases globally.